Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01643564
Other study ID # 1111M06547
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 2011
Est. completion date June 2012

Study information

Verified date October 2023
Source University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Measurement of cytokine levels in post-cardiac transplant patients with unexplained graft dysfunction.


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Group 1 - 18 years and older - Cardiac Transplant recipient with graft dysfunction of unknown etiology Group 2 - 18 years or older - No history of heart failure or cardiac transplantation Group 3 - 18 years or older - Class II-IV heart failure Group 4 - 18 years or older - Heart Transplant 6 months or greater prior to blood draw - No graft dysfunction Exclusion Criteria: Group 1 Heart Transplant with Unexplained Graft Dysfunction - Cellular or antibody-mediated cardiac allograft dysfunction Group 2 Normal Control group - Active infection within 1 month of blood draw - Known Inflammatory Disease Group 3 Heart Failure Group - Active infection within 1 month of blood draw - Known Inflammatory Disease Group 4 Heart Transplant with Normal Graft Function Group - Active infection within 1 month of blood draw - Known graft dysfunction - Known Inflammatory Disease

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in cytokine profiles between stable heart transplant recipients and those with acute rejection Differences in cytokine profiles between stable heart transplant recipients and those with acute rejection 12 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05300451 - Daratumumab in HLA Desensitization Prior to Transplantation Phase 2
Active, not recruiting NCT00695344 - Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant Phase 4
Completed NCT02319278 - DEtection of Cellular Inflammation With FERumoxytol in the HEART Phase 2/Phase 3
Completed NCT00480740 - The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease Phase 3
Active, not recruiting NCT03222531 - Expanding the Pool in Orthotopic Heart Transplantation Phase 2
Terminated NCT00041574 - Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide Phase 2